Review Article

COVİD - 19 from Rheumatology Perspective

10.37696/nkmj.747792

  • Mehmet Engin TEZCAN
  • Rıdvan MERCAN

Received Date: 04.06.2020 Accepted Date: 15.10.2020 Nam Kem Med J 2020;8(3):557-563

World Health Organization declared coronavirus disease-19 (COVID-19) as pandemic since 11 March 2020. Herein, new human coronavirus, SARS-CoV2 is the etiologic agent of the disease. Also, it has been a global health problem since it was detected in Chinese province of Wuhan at December 2019. COVID-19 has several different clinical variations from mild disease to acute respiratory distress syndrome. For the treatment of the disease, several remedies have been administered. Even though, anecdotal data showed somewhat effectiveness of those drugs for the treatment of the disease, there has been no accurate scientific knowledge proofing these. Therefore, main purpose of this review was discussing how the physicians arrange the therapies of the rheumatologic diseases during COVID-19, especially while patients are under immunosuppressive drugs. Also, we summarized the current data about the effectiveness of immunosuppressive drugs on COVID-19.

Keywords: COVID-19, rheumatology, anti-rheumatic drugs

About Journal

Article Tools

Journal Former Name

International Journal of Basic and Clinical Medicine